21st Century Adult Cancer Sourcebook: Small Cell Lung Cancer (SCLC) - Clinical Data for Patients, Families, and Physicians
Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of small cell lung cancer (SCLC). More
Authoritative information and practical advice from the nation's cancer experts about small cell lung cancer (SCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.
Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of small cell lung cancer (SCLC).
Comprehensive data on clinical trials is included - with information on intervention, sponsor, gender, age group, trial phase, number of enrolled patients, funding source, study type, study design, NCT identification number and other IDs, first received date, start date, completion date, primary completion date, last updated date, last verified date, associated acronym, and outcome measures.
Small cell lung cancer (SCLC) accounts for approximately 15% of bronchogenic carcinomas. The overall incidence and mortality rates of SCLC in the United States have decreased during the past few decades. Without treatment, SCLC has the most aggressive clinical course of any type of pulmonary tumor, with median survival from diagnosis of only 2 to 4 months. Compared with other cell types of lung cancer, SCLC is more responsive to chemotherapy and radiation therapy; however, a cure is difficult to achieve because SCLC has a greater tendency to be widely disseminated by the time of diagnosis. It is the cancer most commonly associated with paraneoplastic syndromes, including the syndrome of inappropriate antidiuretic hormone secretion, paraneoplastic cerebellar degeneration, and Lambert-Eaton myasthenic syndrome.
Extensive supplements, with chapters gathered from our Cancer Toolkit series and other reports, cover a broad range of cancer topics useful to cancer patients. This edition includes our exclusive Guide to Leading Medical Websites with updated links to 81 of the best sites for medical information, which let you quickly check for updates from the government and the best commercial portals, news sites, reference/textbook/non-commercial portals, and health organizations. Supplemental coverage includes:
Levels of Evidence for Cancer Treatment Studies
Glossary of Clinical Trial Terms
Clinical Trials Background Information and In-Depth Program
Clinical Trials at NIH
How To Find A Cancer Treatment Trial: A Ten-Step Guide
Taking Part in Cancer Treatment Research Studies
Access to Investigational Drugs
Clinical Trials Conducted by the National Cancer Institute's Center for Cancer Research at the National Institutes of Health Clinical Center
Taking Time: Support for People with Cancer
Facing Forward - Life After Cancer Treatment
Chemotherapy and You
Available ebook formats: